LIC increases its stake in Dr Reddy's Laboratories from 5.65 percent to 7.7 percent

LIC's holding in the company stands at 7.7 percent, it added.

Published On 2022-10-04 05:31 GMT   |   Update On 2022-10-04 05:31 GMT

New Delhi: Pharma major Dr Reddy's Laboratories Ltd on Monday said Life Insurance Corporation of India has increased its stake to 7.7 percent in the pharmaceutical firm through the purchase of 33.86 lakh shares from the open market over some time.Life Insurance Corporation of India (LIC) earlier held around a 5.65 percent stake in the company, Dr Reddy's Laboratories (DRL) said in a...

Login or Register to read the full article

New Delhi: Pharma major Dr Reddy's Laboratories Ltd on Monday said Life Insurance Corporation of India has increased its stake to 7.7 percent in the pharmaceutical firm through the purchase of 33.86 lakh shares from the open market over some time.

Life Insurance Corporation of India (LIC) earlier held around a 5.65 percent stake in the company, Dr Reddy's Laboratories (DRL) said in a regulatory filing.

Between June 15, 2022, and September 30, 2022, LIC purchased 33,86,486 shares of DRL, aggregating a 2.034 percent stake from the open market, it added.
Subsequently, LIC's holding in the company stands at 7.7 percent, it added.

Read also: LIC reduces stake in Sun Pharma; sells shares worth Rs 3,821 crore in over 1 year

Established on 1 September 1956, Life Insurance Corporation of India (LIC) is an Indian statutory body headquartered in Mumbai, Maharashtra, India. The statutory body is under the ownership of Ministry of Finance, Government of India.

Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company headquartered in Hyderabad, Telangana, India. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.

Dr. Reddy's operates in markets across the globe. The company's major markets include - USA, India, Russia & CIS countries, and Europe.

Read also: Dr Reddy's Labs, DNDi ink pact to develop affordable drugs for neglected tropical diseases

Tags:    
Article Source : with inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News